Chiesi to buy KalVista in $1.9B deal for rare disease drug
Summary
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging o...
Description
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging o...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source